CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Monoferric Iron (III) Isomaltoside 1000 iron deficiency anemia Reimburse with clinical criteria and/or conditions Complete
Monoprost latanoprost glaucoma and ocular hypertension Reimburse with clinical criteria and/or conditions Complete
Movapo apomorphine hydrochloride Parkinson's disease Reimburse with clinical criteria and/or conditions Complete
Mozobil Plerixafor Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma Do not list Complete
Multaq Dronedarone hydrochloride Atrial fibrillation Do not list Complete
Mvasi Bevacizumab mCRC NSCLC Biosimilar N/A Complete
Myalepta metreleptin Leptin deficiency in lipodystrophy Reimburse with clinical criteria and/or conditions Active
Myfortic Mycophenolate sodium Organ rejection in allogeneic renal transplants, Prophylaxis List in a similar manner to other drugs in class Complete
Myinfla colchicine Atherothrombotic events in coronary artery disease Do not reimburse Complete
Mylotarg Gemtuzumab Ozogamicin Acute Myeloid Leukemia (AML) Reimburse Complete
Myozyme Alglucosidase Pompe's disease List with clinical criteria and/or conditions Complete
Myrbetriq Mirabegron Overactive bladder Withdrawn
Myrbetriq Mirabegron Overactive bladder List with criteria/condition Complete
N/A everolimus Renal angiomyolipoma associated with tuberous sclerosis complex Reimburse with clinical criteria and/or conditions Active
N/A panitumumab Left-sided metastatic colorectal cancer (mCRC) Reimburse with clinical criteria and/or conditions Active
N/A nab-paclitaxel Gastrointestinal cancer Pending
N/A imiquimod Gynecological cancers Withdrawn
N/A everolimus Tuberous Sclerosis Complex (TSC) Active
N/A mepolizumab Eosinophilic Granulomatosis with Polyangiitis Active
N/A Nab-paclitaxel Gastrointestinal cancer Active
N/A eltrombopag Severe Aplastic Anemia (SAA) Reimburse with clinical criteria and/or conditions Complete
N/A rivaroxaban Venous thromboembolic events (VTE) Reimburse with clinical criteria and/or conditions Active
N/A Enzalutamide Genito-urinary cancer (prostate cancer) Active
N/A blinatumomab Acute lymphoblastic leukemia, pediatrics Pending
N/A nab-paclitaxel Solid tumours Active
Last Updated : June 30, 2024